Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial

A C Vilmar, E Santoni-Rugiu, J B Sorensen

18 Citationer (Scopus)

Abstract

Platinum-based doublets (PBDs) remain the cornerstone of treatment in non-small-cell lung cancer (NSCLC) and may include gemcitabine. A biomarker predicting sensitivity to this antimetabolite would represent a major step forward. Accordingly, we explored the predictive role of ribonucleotide reductase subunit M (RRM1) in advanced NSCLC.
OriginalsprogEngelsk
TidsskriftAnnals of oncology : official journal of the European Society for Medical Oncology / ESMO
Vol/bind24
Udgave nummer2
Sider (fra-til)309-14
Antal sider6
ISSN0923-7534
DOI
StatusUdgivet - feb. 2013

Fingeraftryk

Dyk ned i forskningsemnerne om 'Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial'. Sammen danner de et unikt fingeraftryk.

Citationsformater